Provided by Tiger Trade Technology Pte. Ltd.

Seres Therapeutics

6.85
+0.03500.51%
Post-market: 6.850.00000.00%16:10 EDT
Volume:118.70K
Turnover:803.26K
Market Cap:66.29M
PE:-1.32
High:7.10
Open:6.80
Low:6.52
Close:6.81
52wk High:29.98
52wk Low:5.31
Shares:9.68M
Float Shares:7.38M
Volume Ratio:1.30
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1698
EPS(LYR):0.0175
ROE:-121.87%
ROA:-38.88%
PB:2.50
PE(LYR):391.08

Loading ...

Seres says Phase 1b trial shows SER-155 shifts gut microbiome in allo-HCT patients

Reuters
·
Apr 20

Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026

GlobeNewswire
·
Apr 20

Seres Therapeutics presents at CARB-X Investor Day, highlights SER-428 development

Reuters
·
Apr 09

Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date

TIPRANKS
·
Mar 17

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 14

Canaccord Genuity Remains a Buy on Seres Therapeutics (MCRB)

TIPRANKS
·
Mar 13

Seres Therapeutics reports FY25 EPS 64c

TIPRANKS
·
Mar 12

Seres Therapeutics Q4 EPS $(1.76) Beats $(2.22) Estimate, Sales $438.000K Miss $5.875M Estimate

Benzinga
·
Mar 12

Seres Therapeutics FY2025 net income from continuing operations was USD 5.7 million

Reuters
·
Mar 12

BRIEF-Seres Therapeutics FY EPS USD 0.64

Reuters
·
Mar 12

Seres Therapeutics FY Collaboration Revenue USD 789 Thousand

THOMSON REUTERS
·
Mar 12

Seres Therapeutics FY Operating Income USD -93.971 Million

THOMSON REUTERS
·
Mar 12

Seres Therapeutics FY Net Income USD 5.696 Million

THOMSON REUTERS
·
Mar 12

Seres Therapeutics FY Operating Expenses USD 94.76 Million

THOMSON REUTERS
·
Mar 12

Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
Mar 12

Seres Therapeutics Files Initial Beneficial Ownership Statement for EVP and COO Brady Kelly M. Brady

Reuters
·
Mar 12

Seres Therapeutics Inc expected to post a loss of $2.11 a share - Earnings Preview

Reuters
·
Mar 09

Seres Therapeutics Announces Executive Leadership Changes and Promotions

TIPRANKS
·
Mar 03

Seres co-CEOs Tom DesRosier, Marella Thorell to step down

TIPRANKS
·
Mar 03

Seres Therapeutics names Richard N. Kender Executive Chair and Interim CEO

Reuters
·
Mar 03